摘要
目的:分析3.0T MRI增强扫描在瘢痕妊娠(CSP)中的临床应用。方法:研究对象为2018年7月-2019年5本院收治的50例拟诊CSP的患者,均有完整超声、3.0T MRI影像学检查结果,并经手术病理确诊。以病理诊断结果为金标准,绘制受试者工作特征(ROC)曲线,分析3.0T MRI增强扫描在瘢痕妊娠的临床应用价值。结果:MRI诊断CSP 38例,非CSP 12例,与病理结果对照,MRI诊断CSP的曲线下面积值为0.871(0.706~1.000),约登指数0.741,敏感度为92.31%,特异度为81.82%;超声诊断35例CSP,非CSP 15例,与病理结果对照,超声诊断CSP的曲线下面积值为0.774(0.604~0.944),约登指数0.548,敏感度为82.05%,特异度为72.73%;MRI诊断CSP的曲线下面积值高于超声,诊断CSP的敏感度、特异度也高于超声,但差异无统计学意义(χ^2=1.835、0.114,P=0.175、0.735)。结论:相较于超声,3.0T MRI增强扫描用于瘢痕妊娠诊断具有更高的诊断价值,或可为CSP患者的临床治疗提供更全面的疾病信息,值得临床重视。
Objective:To analyze the clinical application of 3.0T MRI enhancement scan in cesarean scar pregnancy(CSP).Method:A total of 50 patients with CSP who admitted to our hospital from July 2018 to May 2019 were selected as subjects.They all had complete ultrasound,3.0T MRI findings and were diagnosed by surgical pathology.With the result of pathological diagnosis as the golden standard,the receiver operating characteristic(ROC)curves were plotted to analyze the clinical application value of 3.0T MRI enhancement scan in CSP.Result:MRI diagnosed 38 cases with CSP and 12 cases without,compared with pathological results,the area under the curve of MRI for diagnosis of CSP was 0.871(0.706-1.000),Youden index,sensitivity and specificity were 0.741,92.31%and 81.82%,respectively.Ultrasound diagnosed 35 cases with CSP and 15 cases without,compared with pathological results,the area under the curve of ultrasound for diagnosis CSP was 0.774(0.604-0.944),Youden index,sensitivity and specificity were 0.548,82.05%and 72.73%,respectively.The area under the curve of MRI for diagnosis CSP was larger than that of ultrasound,the sensitivity and specificity were higher than those of ultrasound,but the differences were not seatisticdly significant(χ^2=1.835,0.114,P=0.175,0.735).Conclusion:Compared with ultrasound,3.0T MRI enhancement scan has a greater diagnostic value for CSP.It can provide more comprehensive disease information for clinical treatment of CSP,which is worthy of clinical attention.
作者
占波
王亚
江文婷
王宏菁
刘建军
ZHAN Bo;WANG Ya;JIANG Wenting;WANG Hongjing;LIU Jianjun(Shangrao City People’s Hospital,Shangrao 334000,China)
出处
《中国医学创新》
CAS
2019年第31期133-136,共4页
Medical Innovation of China
基金
江西省卫生计生委科技计划项目(20197450)